Drug Discovery

How is Constructive Bio Revolutionizing Synthetic Genomics Technology?
Research & Development How is Constructive Bio Revolutionizing Synthetic Genomics Technology?

Biotechnology startup Constructive Bio has recently garnered attention for its innovative advances in synthetic genomics and engineered protein translation. Winning the Innovation Award at the ELRIG Drug Discovery 2024 event highlights the transformative potential of their technologies. This

AI-Driven Collaboration Enhances Efficiency in Drug Development
Research & Development AI-Driven Collaboration Enhances Efficiency in Drug Development

AI-Driven Collaboration Enhances Efficiency in Drug Development The landscape of drug development is undergoing a transformative shift. Today, advanced technologies like artificial intelligence (AI) are converging with traditional laboratory practices, promising a new era of efficiency and

Will Aktis Oncology Lead the Radiopharma Cancer Treatment Revolution?
Research & Development Will Aktis Oncology Lead the Radiopharma Cancer Treatment Revolution?

Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to

BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs
Research & Development BioAge's $198M IPO Marks Major Shift Towards Innovative Obesity Drugs

BioAge Labs has recently garnered significant attention with its successful initial public offering (IPO), raising a formidable $198 million. Demonstrating the company's strategic pivot towards obesity drug research, this financial feat is particularly notable given the challenging environment

Engaging Biopharma and Government to Combat Resurgent Mpox
Research & Development Engaging Biopharma and Government to Combat Resurgent Mpox

Mpox has made a concerning comeback, compelling immediate and collaborative action. With an increased threat from the Clade Ib strain, the situation demands an effective response framework modeled after successful strategies used in the COVID-19 pandemic. This involves substantial input from both

Can MinervaX and Wacker Biotech Transform GBS Prevention?
Research & Development Can MinervaX and Wacker Biotech Transform GBS Prevention?

In a significant move for maternal and neonatal healthcare, Danish biotech company MinervaX has teamed up with German CDMO Wacker Biotech to develop a groundbreaking prophylactic vaccine for Group B Streptococcus (GBS) infections. This partnership marks a pivotal step in addressing a critical unmet

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later